Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities

Rhea-AI Summary

Moderna (NASDAQ:MRNA) is expanding U.S. manufacturing by onshoring Drug Product capabilities to its Moderna Technology Center in Norwood, Massachusetts. The project includes a >$140 million investment and is expected to create hundreds of biomanufacturing jobs, enabling full end-to-end mRNA manufacturing in the U.S. for commercial and clinical supply. Construction has started and Moderna is targeting completion by the first half of 2027. The move reinforces Moderna's domestic manufacturing footprint and supports its pipeline of mRNA vaccines and therapeutics across infectious diseases, cancer, rare diseases, and autoimmune disorders.

Positive

• $140 million+ investment in U.S. manufacturing
• Completes end-to-end mRNA manufacturing in the U.S.
• Creates hundreds of skilled biomanufacturing jobs
• Supports both commercial and clinical supply

Negative

• Construction timeline extends to H1 2027, exposing schedule risk
• Capital spend >$140M may affect near-term cash allocation

Insights

Manufacturing Strategy Expert

Onshoring final Drug Product steps completes U.S. end-to-end mRNA manufacturing and adds material capacity and jobs.

Moderna consolidates fill/finish and finishing steps at its Moderna Technology Center in Norwood, Massachusetts, enabling domestic end-to-end production for commercial and clinical mRNA supply. The company cites a $140 million investment and creation of "hundreds" of highly skilled biomanufacturing jobs; construction has started with target completion by first half of 2027.

The operational effect is clearer internal control over supply chain and reduced cross-border handoffs, which can shorten lead times and simplify regulatory oversight. Realized benefits will depend on timely construction, validation, regulatory inspections, and workforce hiring; any delays in those steps could postpone the stated capacity gains.

Watch execution milestones: construction progress, facility qualification/validation, regulatory approvals for commercial supply, and hiring timelines through first half of 2027. These discrete milestones will indicate whether the announced $140 million buildout converts into usable domestic capacity within the stated timeframe.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network

More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to its existing Moderna Technology Center ("MTC") in Norwood, Massachusetts. Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the U.S. This milestone marks a significant step in strengthening Moderna's U.S. manufacturing network, supporting both commercial and clinical supply, and reinforcing the Company's commitment to domestic mRNA production.

"By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," said Stéphane Bancel, Chief Executive Officer of Moderna. "As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community."

The expansion reflects Moderna's ongoing investment in U.S.-based infrastructure and its commitment to build a robust, domestic manufacturing platform capable of supporting its pipeline of mRNA vaccines and therapeutics. Moderna's innovative mRNA platform, first widely recognized globally during the Company's partnership with the U.S. Government through Operation Warp Speed, continues to drive potential biomedical breakthroughs across infectious diseases, cancer, rare diseases and autoimmune disorders.

Construction at MTC for the new Drug Product manufacturing capability has started with Moderna targeting completion by the first half of 2027.

About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's U.S. manufacturing network and ongoing investment in U.S.-based infrastructure; the potential of Moderna's mRNA platform; Moderna's targeted completion of its new Drug Product manufacturing capability by the first half of 2027; and expected job creation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Moderna (MRNA) announce on November 19, 2025 about U.S. manufacturing?

Moderna announced onshoring of Drug Product manufacturing to Norwood, MA, creating full U.S. end-to-end mRNA production.

How much is Moderna investing in the Norwood Drug Product expansion (MRNA)?

Moderna is investing more than $140 million in the Norwood Drug Product manufacturing expansion.

When will Moderna (MRNA) complete the Norwood Drug Product facility expansion?

Moderna is targeting completion by the first half of 2027.

How many jobs will Moderna's Norwood expansion create for MRNA shareholders to note?

The company says the investment will create hundreds of highly skilled biomanufacturing jobs.

What does onshoring Drug Product manufacturing mean for Moderna (MRNA) supply?

Onshoring enables full end-to-end manufacturing in the U.S., supporting both commercial and clinical supply.